Clinical trial · Interventional
The Influence of Perioperative Administration of Dexmedetomidine on Inflammation Response and Postoperative Outcomes in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Double Blind Randomized Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) has been reported to be an effective treatment approach for peritoneal cancer, however, the stress response to HIPEC is major neuroendocrine and cytokine response, which has been considered as the homeostatic defense mechanism. Recently, dexmedetomidine has been suggested to exhibit anti-inflammatory properties. This study was designed to evaluate the effect of perioperative administration of dexmedetomidine on inflammation response and postoperative outcomes in patients undergoing hyperthermic intraperitoneal chemotherapy (HIPEC) cytoreductive surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dexmedetomidine | Drug | — | UNRESOLVED |
| Normal saline | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- dexmedetomidine infusion group
- interventionNames
- Drug: dexmedetomidine
- type
- ACTIVE_COMPARATOR
- label
- normal saline infusion group
- interventionNames
- Drug: Normal saline
Primary outcomes (1)
- measure
- IL-6 level
- timeFrame
- Up to 12 hours after surgery
- description
- To evaluate the effect of dexmedetomidine on the level of IL-6 in patient undergoing HIPEC, IL-6 level was measured up to 12 hours after surgery.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * patients between 20 and 70 years old * obtaining written informed consent from the patients who were undergoing hyperthermic intraperitoneal chemotherapy (HIPEC) cytoreductive surgery * weights under 90 kg and BMI under 32 Exclusion Criteria: * emergency operation * re-operations * combined surgery over 4 departments. * cardiac disease (unstable angina, congestive heart failure, valvular heart disease) * Ventricular conduction abnormality * prior pacemaker insertion * uncontrolled hypertension (diastolic blood pressure \> 110mmHg) * bradycardia (HR \< 40 Bpm) * cerebral vascular disease (cerebral hemorrhage, cerebral ischemia) * hepatic or renal failure * patients who take antiarrythmic agent * neurological or psychiatric illnesses * foreigner and patient who can not read the letter
References
Publications (0)
Data not yet available